Update on the Surgical Management of Fuchs Endothelial Corneal Dystrophy

• Main Authors: Andrea L. Blitzer, Kathryn A. Colby
• Format: Article
• Language: English
• Published: Adis, Springer Healthcare 2020-08-01
• Series: Ophthalmology and Therapy
• Subjects: Corneal transplantation; Descemetorhexis; Descemet membrane endothelial keratoplasty; Descemet stripping; Descemet stripping automated endothelial keratoplasty; Fuchs dystrophy
• Online Access: https://doi.org/10.1007/s40123-020-00293-3
• ISSN: 2193-8245; 2193-6528

Abstract Fuchs endothelial corneal dystrophy (FECD) is the most common posterior corneal dystrophy and the leading indication for corneal transplantation in the United States. FECD is slowly progressive, and patients develop gradual corneal endothelial decompensation, eventually resulting in failure of the endothelium to maintain corneal deturgescence. Medical management consists of topical hyperosmotic agents to facilitate dehydration of the cornea, but surgical intervention is often required to regain corneal clarity. The surgical management of FECD has evolved over the past two decades as corneal transplantation techniques have allowed for more selective keratoplasty and replacement of only the diseased layers of the cornea. Prior surgical management consisted of penetrating keratoplasty (PK) that carried significant intraoperative risks associated with “open sky” as well as postoperative risks of graft rejection, wound dehiscence, postoperative astigmatism, and prolonged visual rehabilitation. In the past 15 years, endothelial keratoplasty (EK) has become the treatment of choice for endothelial disease, significantly reducing the risks associated with the surgical treatment of FECD. Here we discuss the current surgical management of FECD, including the introduction of Descemet stripping only (DSO), and highlight future investigative efforts.